Asnis G M, Friedman J M, Miller A H, Iqbal N, Lo E S, Cooper T B, Halbreich U, Lemus C Z, van Praag H M, Rubinson E
Department of Psychiatry, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY.
J Affect Disord. 1989 Jan-Feb;16(1):5-10. doi: 10.1016/0165-0327(89)90048-7.
We investigated the 1-mg dexamethasone suppression test (DST) in 41 outpatients with major depressive disorder assessing the role of dexamethasone blood level, age and basal cortisol on DST results. Non-suppressors (approximately 25% of patients) had lower dexamethasone levels, and post-dexamethasone cortisol was negatively correlated with plasma dexamethasone; these findings were more significant after covarying out age and basal cortisol, factors that were also significantly associated to non-suppressors. A subgroup of patients (n = 19) also had 0.75-mg and 2.0-mg DST to evaluate whether a threshold dexamethasone blood level existed; a dexamethasone blood level greater than 1.5 ng/ml converted all non-suppressors to suppressors. Implications of these findings are discussed.
我们对41名重度抑郁症门诊患者进行了1毫克地塞米松抑制试验（DST），评估地塞米松血药浓度、年龄和基础皮质醇对DST结果的作用。未被抑制者（约占患者的25%）地塞米松水平较低，且地塞米松给药后的皮质醇与血浆地塞米松呈负相关；在排除年龄和基础皮质醇（这两个因素也与未被抑制者显著相关）后，这些发现更为显著。一组患者（n = 19）还进行了0.75毫克和2.0毫克的DST，以评估是否存在地塞米松血药浓度阈值；地塞米松血药浓度大于1.5纳克/毫升可使所有未被抑制者转变为被抑制者。本文讨论了这些发现的意义。
